Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2000 Oct;17(10):1278-83.
doi: 10.1023/a:1026451721686.

Confidence interval criteria for assessment of dose proportionality

Affiliations

Confidence interval criteria for assessment of dose proportionality

B P Smith et al. Pharm Res. 2000 Oct.

Abstract

Purpose: The aim of this work was a pragmatic, statistically sound and clinically relevant approach to dose-proportionality analyses that is compatible with common study designs.

Methods: Statistical estimation is used to derive a (1-alpha)% confidence interval (CI) for the ratio of dose-normalized, geometric mean values (Rdnm) of a pharmacokinetic variable (PK). An acceptance interval for Rdnm defining the clinically relevant, dose-proportional region is established a priori. Proportionality is declared if the CI for Rdnm is completely contained within the critical region. The approach is illustrated with mixed-effects models based on a power function of the form PK = beta0 x Dose(beta1); however, the logic holds for other functional forms.

Results: It was observed that the dose-proportional region delineated by a power model depends only on the dose ratio. Furthermore, a dose ratio (rho1) can be calculated such that the CI lies entirely within the pre-specified critical region. A larger ratio (rho2) may exist such that the CI lies completely outside that region. The approach supports inferences about the PK response that are not constrained to the exact dose levels studied.

Conclusion: The proposed method enhances the information from a clinical dose-proportionality study and helps to standardize decision rules.

PubMed Disclaimer

References

    1. Pharm Res. 1993 Feb;10(2):289-93 - PubMed
    1. J Clin Pharmacol. 1992 Aug;32(8):716-24 - PubMed
    1. J Pharm Sci. 1988 Sep;77(9):779-83 - PubMed
    1. J Pharmacokinet Biopharm. 1976 Dec;4(6):537-51 - PubMed
    1. J Clin Pharmacol. 1996 Aug;36(8):732-9 - PubMed

LinkOut - more resources